ReviewFrontiers in immunology2026
Molecular PET and immuno-PET in gastric cancer immunotherapy: current evidence, clinical utilities, and translational barriers.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This mini-review aims to examine how molecular PET and immuno-PET may complement tissue-based biomarkers in gastric cancer immunotherapy by enabling whole-body assessment of target expression, stromal biology, immune effector activity, and treatment-related inflammatory changes. Gastric cancer remains a major global health burden, while immunotherapy is expanding from advanced disease into perioperative and conversion settings. However, clinical benefit remains heterogeneous, and conventional biomarkers such as PD-L1, HER2, and MSI/dMMR do not fully capture spatial and temporal variation across lesions. Molecular PET broadly encompasses tracers targeting metabolism, receptors, stromal components, and immune biology, whereas immuno-PET uses radiolabeled antibodies or related scaffold proteins to visualize target distribution and, in some settings, pharmacodynamic changes
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.